An abstract published in Annals of Oncology summarizes the 10-year survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in patients with advanced melanoma. These final results represent the longest reported in a phase III study of an anti–PD-1–based therapy for any tumor type.
